Lisinopril (Prinivil)

Subscribe to Selected New Research on Lisinopril

795 relevant articles (97 outcomes, 218 trials/studies) found for this Drug

Description: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.

Also Known As:

Prinivil; Zestril; Lisinopril Maleate (1:1); Lisinopril Sulfate (1:2); Lysinopril; MK-521; L-Proline, 1-(N2-(1-carboxy-3-phenylpropyl)-L-lysyl)-, dihydrate, (S)-

Relationship Network

Drug Context: Research Results

Amino Acids, Peptides, and Proteins

18F-fluorobenzoyl-lisinopril

Experts

1.	Poole-Wilson, P A: 3 articles (12/2000 - 08/2000)
2.	Armstrong, P W: 3 articles (12/2000 - 08/2000)
3.	Massie, B M: 3 articles (12/2000 - 08/2000)
4.	Horowitz, J D: 3 articles (12/2000 - 08/2000)
5.	Vataman, Eleonora: 2 articles (08/2008 - 11/2007)
6.	Begović, Begler: 2 articles (08/2008 - 11/2007)
7.	Hima, Faik: 2 articles (08/2008 - 11/2007)
8.	Gerc, Vjekoslav: 2 articles (08/2008 - 11/2007)
9.	Vehabović, Midhat: 2 articles (08/2008 - 11/2007)
10.	Kusljugić, Zumreta: 2 articles (08/2008 - 11/2007)

Related Diseases

1.	Hypertension (High Blood Pressure) 02/01/1997 - "The efficacy of lisinopril in reducing blood pressure is well established in younger populations, and many trials now show it to be effective in lowering blood pressure in elderly patients with hypertension" 12/01/2001 - "In conclusion, supervised lisinopril therapy is effective in controlling hypertension in chronic HD patients" 01/01/1994 - "The main objective of this multicenter study was to compare the efficacy of an increase in dose and of a synergic combination in the 68 patients out of 126 (54%) with hypertension (DBP between 95 and 120 mm Hg after 2 weeks of placebo) who did not respond (DBP > or = 95 mmHg) to a 4-week treatment of 20 mg per day of lisinopril" 01/01/1990 - "Thus, lisinopril at 20 or 40 mg once daily proved both well tolerated and effective in reducing blood pressure in patients with mild to moderate essential hypertension." 03/01/1993 - "The results of the efficacy analysis confirm the established efficacy of lisinopril in patients with mild to moderate essential hypertension." Get all the results and reference details, order at left...
2.	Heart Failure 12/01/2000 - "AIMS: An analysis was designed to determine whether chronic heart failure patients at high cardiovascular risk benefited to the same extent from high-dose lisinopril as the whole ATLAS population" 04/01/1998 - "ATLAS: high dose lisinopril is superior to low dose in heart failure." 08/20/2000 - "A prospective study was performed in patients (30 M, 16 F, mean age of 56.0 +/- 9.2 [42-73] years) with congestive heart failure to assess the efficacy of lisinopril during a 16 weeks treatment period" 06/01/2003 - "STUDY DESIGN: A 19-nation RCT of high-dose (32.5-35.0 mg/day) versus low-dose (2.5-5.0 mg/day) lisinopril in 3164 patients with class II-IV heart failure and left ventricular ejection fraction < or = 30%" 09/01/2002 - "METHODS: Twelve patients with symptomatic heart failure completed a randomized double-blind crossover trial of lisinopril 5 mg o.d" Get all the results and reference details, order at left...
3.	Myocardial Infarction 05/01/2000 - "Lisinopril is safe and effective when given early after the onset of myocardial infarction, regardless of a concomitant administration of ASA started early and continued over a 6-week period." 08/01/2005 - "In the Antihypertensive and Lipid Lowering to Prevent Heart Attack Trial, lisinopril-treated patients had a slightly lower incidence of myocardial infarction, despite much poorer control of blood pressure, perhaps because a second-line diuretic was prohibited by protocol" 05/01/2000 - "The aim of the study was to verify the possible negative interaction between ASA and the ACEi lisinopril in the postacute phase of acute myocardial infarction" 05/01/2000 - "The authors analyzed a database of 18,895 patients of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardio-3 (GISSI-3) Trial in which patients were allocated either to receive lisinopril or not to receive lisinopril within 24 hours of the onset of symptoms of myocardial infarction" 12/16/1997 - "Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study." Get all the results and reference details, order at left...
4.	Proteinuria 01/01/1991 - "It has been shown in one study to decrease proteinuria as effectively as lisinopril, and it may have renal protective effects" 01/01/1996 - "In the lisinopril- and in the ZD7155-treated rats, a comparable systolic pressure control was achieved (121 +/- 12 and 118 +/- 14 mm Hg, respectively), and proteinuria was significantly prevented (averaging only 38 +/- 23 and 30 +/- 8 mg/24h, respectively) at the end of the study" 01/01/2006 - "At week 6, proteinuria was stabilized (195 +/- 172 mg/24 h), a renal biopsy was performed for analysis of preceding damage and rats were instituted on lisinopril for 6 weeks until sacrifice at week 12" 03/01/2005 - "Residual proteinuria (median, 3.2 g/d; 95% confidence interval, 1.8 to 5.2 g/d) was significantly reduced with 55.6% (95% confidence interval, 16.0 to 73.2%; P < 0.02) on the maximal additional tolerated dose of lisinopril" 07/01/2003 - "1D11 and lisinopril kept proteinuria at levels numerically lower than irrelevant antibody and saline, while CAT-192 was ineffective" Get all the results and reference details, order at left...
5.	Fibrosis (Cirrhosis) 06/01/2000 - "OBJECTIVES: This study was designed to assess the long-term effects of lisinopril on mortality, cardiac function, and ventricular fibrosis after MI, in rats" 07/01/1992 - "In treatment trials, where reactive fibrosis was established, lisinopril promoted regression of the fibrosis and therefore was cardioprotective" 08/01/2002 - "Lisinopril exerted a potent antiproteinuric effect and suppressed the progression of both glomerulosclerosis and tubulointerstitial fibrosis" 08/01/1996 - "Lisinopril-mediated regression of myocardial fibrosis." 04/01/1992 - "With a low dose of lisinopril that does not reduce blood pressure significantly, only the excessive fibrosis is reversed" Get all the results and reference details, order at left...
194 Diseases and 795 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
2.	Captopril (Capoten)
3.	Nifedipine (Adalat)
4.	Enalapril
5.	Hydrochlorothiazide (Esidrix)
6.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
7.	Amlodipine (Norvasc)
8.	Losartan (Cozaar)
9.	valsartan (Vals)
10.	Metoprolol (Lopressor)
338 Drugs and Important Bio-Agents and 593 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Transplantation (Transplant Recipients)
2.	Aftercare (After-Treatment)
3.	Kidney Transplantation
4.	Transplants (Transplant)
5.	Peritoneal Dialysis
19 Therapies and Procedures and 32 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>